Press release
Hypertriglyceridemia Pipeline 2025: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis by DelveInsight | Merck, Julphar, Eli Lilly and Company, Bristol-Myers Squibb Company
"Hypertriglyceridemia Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/hypertriglyceridemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypertriglyceridemia Market.
The Hypertriglyceridemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Hypertriglyceridemia Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Hypertriglyceridemia treatment therapies with a considerable amount of success over the years.
*
Hypertriglyceridemia companies working in the treatment market are Eli Lilly and Company, OrsoBio, Marea Therapeutics, Arrowhead Pharmaceuticals, NorthSea Therapeutics, Ionis Pharmaceuticals, 89bio, Inc., and others, are developing therapies for the Hypertriglyceridemia treatment
*
Emerging Hypertriglyceridemia therapies in the different phases of clinical trials are- LY3875383, TLC-2716, MAR001, ARO-APOC3, NST-1024, Olezarsen, Pegozafermin, and others are expected to have a significant impact on the Hypertriglyceridemia market in the coming years.
*
In May 2025, Ionis Pharmaceuticals reported positive topline results from the global Phase III Essence trial of Tryngolza (olezarsen) in individuals with moderate hypertriglyceridemia and/or at risk of atherosclerotic cardiovascular disease (ASCVD). Characterized by fasting triglyceride (TG) levels between greater than or equal to 150mg/dL and
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypertriglyceridemia Pipeline 2025: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis by DelveInsight | Merck, Julphar, Eli Lilly and Company, Bristol-Myers Squibb Company here
News-ID: 4066306 • Views: …
More Releases from ABNewswire
Top Trends in Digital Marketing to Watch in 2025
Let's be honest, digital marketing changes so fast, it's almost impossible to keep up. What worked last year is most likely outdated by now. And in 2025, things are moving even faster.
Why? Because the game is increasingly controlled by media companies that own everything. They set the rules, they control the platforms, and they influence how we create and consume content. But that doesn't mean smaller businesses or independent marketers…
Faster Anemia Recovery: When to Switch From Iron Pills to IV Iron
Iron deficiency anemia is exhausting. When your iron is low, everyday tasks feel heavier, your focus slips, and even simple workouts become harder. Oral iron supplements are usually the first step, but they don't always work fast enough-especially if your levels are very low or your body struggles to absorb iron.
That's where IV iron becomes a more efficient option. It delivers iron directly into your bloodstream, giving your body what…
Is Laser Hair Removal Safe for All Skin Tones? The Latest Technology Claims "Yes …
For years, laser hair removal was widely thought to be safest and most effective only for people with lighter skin and darker hair. That belief came from the limitations of early laser technology, which struggled to distinguish between pigment in the hair follicle and pigment in the skin. As a result, individuals with medium, dark, or very dark skin tones were often told they weren't good candidates.
Fortunately, the landscape has…
How Factoring Services Help Businesses with Late Payments
US customers pay their invoices late in over 50% of cases, causing cash flow disruptions, missed opportunities, and financial strain. Factoring services can fix these issues for you in almost no time. This financial solution converts unpaid invoices into immediate working capital in 24 hours.
If late payments are a constant challenge for your business, learn how you can take advantage of factoring to tackle it.
1. Get a steady cash flow
More…
More Releases for Hypertriglyceridemia
Hypertriglyceridemia Market to Reach USD 23.94 Billion by 2034
Pune, India - December 2025 - The global Hypertriglyceridemia Market, valued at USD 13.12 billion in 2024, is projected to reach USD 23.94 billion by 2034, growing at a 6.1% CAGR (2025-2034), according to Exactitude Consultancy. Rising prevalence of obesity, type 2 diabetes, metabolic syndrome, and cardiovascular disease is driving strong demand for triglyceride-lowering therapies worldwide.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72029
Market Summary
The Hypertriglyceridemia Market is expanding…
Severe Hypertriglyceridemia Market to Reach USD 5.42 Billion by 2034
Pune, India - December 2025 - The global Severe Hypertriglyceridemia (SHTG) Market, valued at USD 3.07 billion in 2024, is projected to reach USD 5.42 billion by 2034, growing at a 5.7% CAGR (2025-2034), according to Exactitude Consultancy. The increasing prevalence of obesity, diabetes, metabolic syndrome, and cardiovascular diseases is driving strong demand for advanced triglyceride-lowering treatments.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72003
Market Summary
The Severe Hypertriglyceridemia Market…
Hypertriglyceridemia Market is expected to reach USD 39 billion by 2034
Hypertriglyceridemia is a common lipid disorder characterized by elevated levels of triglycerides in the blood, often associated with obesity, diabetes, metabolic syndrome, and genetic predisposition. While mild to moderate hypertriglyceridemia is widespread, severe cases can lead to acute pancreatitis, cardiovascular disease, and liver complications. The condition is both a standalone metabolic issue and a risk factor for a broader spectrum of chronic diseases.
Download Full PDF Sample Copy of Market Report…
Severe Hypertriglyceridemia Treatment Drugs, Pipeline Insights, Emerging Therapi …
DelveInsight's, "Severe Hypertriglyceridemia Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Severe…
Navigating Hypertriglyceridemia: Causes, Risks, and Effective Management Strateg …
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms…
Hypertriglyceridemia: Unraveling the Highs and Lows of Triglyceride Metabolism
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms…
